Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BrightGene Bio-Medical Technology Co., Ltd.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index (BMI) meeting one of the following requirements:
1. Between ≥ 30.0 kg/m2 and ≤ 40.0 kg/m2 (obese); OR
2. Between ≥ 27.0 kg/m2 and \< 30.0 kg/m2 (overweight) with at least 1 of the following: 1) One or more of prediabetes (impaired fasting plasma glucose and/or abnormal glucose tolerance), grade 1 hypertension, simple fatty liver or dyslipidemia; 2) Weight-bearing joint pain; 3) Obesity causing dyspnea or obstructive sleep apnea syndrome
Have a stable body weight (\<5% self-reported change during the previous 8 weeks) before screening
Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.
You may not be if
Have allergic predisposition (allergic to 3 or more foods or drugs), or are allergic to glucagon-like peptide-1 (GLP-1) receptor agonists, or suffer from severe allergic diseases (asthma, urticaria, eczematous dermatitis).
Have received GLP-1 receptor agonists or similar drugs containing the same target within 12 weeks before screening.
Have received drugs that have an impact on body weight within 12 weeks before screening.
Surgical treatment for obesity.
Known type I/II diabetes.
History of acute or chronic pancreatitis or pancreatic injury.
History of drug abuse or alcoholism at screening.
Clareo Health | Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
